GlassScriptPhysician profile
Kurt A Wharton
NPI 1457561086
$6,715.43
in general payments reported to CMS, 2019-2025
60 companies · $1,473 in 2025
The $1,473 reported for 2025 was more than what 87% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $259 · 2021: $542 · 2022: $1,542 · 2023: $1,267 · 2024: $1,155 · 2025: $1,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,895.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elekta, INC. | $559.04 | 2021-2022 | |
| Varian Medical Systems, INC. | $436.28 | 2019-2021 | |
| Blue Earth Diagnostics | $393.91 | 2019-2025 | Posluma |
| Novocure INC. | $374.87 | 2019-2025 | Optune, Optune Lua (Novottf-200t) |
| Astrazeneca Pharmaceuticals LP | $329.23 | 2019-2025 | Imfinzi |
| Janssen Biotech, INC. | $270.69 | 2019-2025 | Erleada, Talvey, Tecvayli |
| Icotec Medical INC. | $259.73 | 2023-2025 | Vader Pedicle System 6.0, Screw, Carbon/Peek, Polyax., Fen., O 5.5 X 45 Mm, Kong-Tl Vbr, End Plate, Rectangular, M and Screw, 12 X 33 Mm, Vader Pedicle System, Rod, Carbon/Peek, Curved, 6.0 R450 X 200 Mm |
| Takeda Pharmaceuticals U.S.A., INC. | $190.99 | 2019-2025 | Fruzaqla, Vpriv |
| Eisai INC. | $186.49 | 2022-2025 | |
| Progenics Pharmaceuticals, INC. | $178.57 | 2023-2025 | Pylarify |
| Daiichi Sankyo INC. | $177.17 | 2020-2025 | Enhertu, Injectafer |
| Pfizer INC. | $176.19 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $175.34 | 2020-2025 | |
| Myriad Genetic Laboratories, INC. | $168.66 | 2021-2025 | Prolaris, Myrisk |
| Molnlycke Health Care US, LLC | $164.75 | 2022 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $163.65 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Regeneron Healthcare Solutions, INC. | $161.46 | 2022-2025 | Libtayo, Lynozyfic |
| Amgen INC. | $144.47 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Abbvie INC. | $138.03 | 2022-2025 | |
| Accuray Incorporated | $119.09 | 2024 | |
| Astellas Pharma US INC | $118.26 | 2019-2025 | Xtandi |
| Genzyme Corporation | $104.02 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.57 | 2019-2025 | |
| Blueprint Medicines Corporation | $96.25 | 2022-2023 | Ayvakit |
| Incyte Corporation | $94.94 | 2022-2023 | Jakafi |
| Glaxosmithkline, LLC. | $88.60 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Medtronic, INC. | $78.66 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.54 | 2020-2023 | Gilotrif |
| Lilly USA, LLC | $69.92 | 2019-2024 | Jaypirca, Retevmo, Verzenio |
| Verity Pharmaceuticals INC. | $67.70 | 2022-2025 | Trelstar |
| Genentech USA, INC. | $64.98 | 2024-2025 | Tecentriq, Polivy, Rozlytrek |
| Tersera Therapeutics LLC | $59.33 | 2022-2023 | Xermelo |
| Genmab U.S., INC. | $59.32 | 2024 | Epkinly, Tivdak |
| Seagen INC. | $57.04 | 2019-2023 | Tukysa |
| Celgene Corporation | $57.01 | 2022 | |
| Carbofix Spine INC | $55.57 | 2024 | |
| Puma Biotechnology, INC. | $46.41 | 2022-2024 | |
| Exelixis INC. | $45.69 | 2019-2024 | Cabometyx |
| Springworks Therapeutics, INC. | $43.96 | 2025 | Ogsiveo, Gomekli |
| Coherus Oncology, INC. | $42.62 | 2022-2024 | |
| Aveo Pharmaceuticals, INC. | $42.42 | 2023-2024 | Fotivda |
| Emd Serono, INC. | $42.10 | 2023-2024 | Tepmetko |
| Kyowa Kirin, INC. | $41.84 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $40.29 | 2019-2025 | Gavreto, Tavalisse, Rezlidhia |
| Pharmacosmos Therapeutics INC. | $31.27 | 2025 | Monoferric |
| Bioprotect Medical, INC. | $30.73 | 2025 | Bioprotect Balloon Implant System |
| Pharming Healthcare, INC. | $29.48 | 2024 | Ruconest |
| Karyopharm Therapeutics INC. | $26.85 | 2022 | |
| Adaptive Biotechnologies Corporation | $26.47 | 2023 | Clonoseq |
| Jazz Pharmaceuticals INC. | $25.64 | 2019-2020 | |
| Stemline Therapeutics INC. | $23.02 | 2024 | Orserdu |
| Cti Biopharma Corp. | $23.02 | 2023 | Vonjo |
| Recordati_rare_diseases_inc. | $22.05 | 2023 | Sylvant |
| Tempus Ai, INC | $20.60 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $19.08 | 2020 | |
| Morphosys, US INC. | $17.32 | 2022 | |
| Fennec Pharmaceuticals, INC. | $16.84 | 2025 | Fyarro |
| Legend Biotech USA INC. | $15.91 | 2025 | Carvykti |
| Tolmar Pharmaceuticals, INC. | $14.62 | 2020 | |
| Digestive Care, INC. | $13.88 | 2024 | Pertzye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Wharton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.